All women should receive a liquid-based Pap test such as the ThinPrep Pap Test, which is labeled by the FDA as “significantly more effective” than the conventional Pap smear for the detection of low-grade and more severe lesions, say proponents, because the test increases the opportunity to detect and treat these types of cervical abnormalities earlier. Today, more than 87 percent of Pap tests in the U.S. are performed with the ThinPrep Pap Test, representing a new standard in cervical cancer screening. To assure that you get this particular test, women should ask for the test by name, they suggest.

The ThinPrep Pap Test employs a fluid transport medium to preserve cells, eliminate debris and distribute a representative portion of cells on a slide in a uniform, even layer. A ThinPrep prepared slide is clear, easy-to-read and free of obscuring blood, mucus and non-diagnostic debris and is significantly more effective than the conventional Pap smear for the detection of low-grade and more severe lesions in a variety of patient populations, they say.

And, while the HPV-vaccine is a remarkable advance in medicine, it’s important for women to know that it won’t replace the need for an annual Pap test for the detection of cervical cancer. The vaccine protects against four types of HPV, which are responsible for only 70 percent of all cervical cancers. A Pap test remains the only way to detect whether cervical cancer is present, they say.

Related posts:

  1. Need For Worldwide Cervical Cancer Prevention
  2. Breast Cancer Missed in 30% According to Study
  3. Prisoners and HIV Testing
  4. New Breast Cancer Test Approved
  5. HPV Vaccine and Men

|



Comments

Name (required)

Email (required)

Website

Leave a comment